The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event
Open accessAbstract
BACKGROUND: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these patients, the course of the disease is unpredictable at its onset and requires long-term observation or repeated magnetic resonance imaging (MRI). We investigated whether the presence of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with a clinically isolated syndrome predicts the interval to conversion to clinically definite multiple sclerosis. METHODS: A total of 103 patients with a clinically isolated syndrome, positive findings on cerebral MRI, and oligoclonal bands in the cerebrospinal fluid were studied. At base line, serum samples were collected to test for anti-MOG and anti-MBP antibodies with Western blot analysis, and the lesions detected by cerebral MRI were quantified. Neurologic examinations for relapse or disease progression (defined as conversion to clinically definite multiple sclerosis) were performed at base line and subsequently every three months. RESULTS: Patients with anti-MOG and anti-MBP antibodies had relapses more often and earlier than patients without these antibodies. Only 9 of 39 antibody-seronegative patients (23 percent) had a relapse, and the mean (+/-SD) time to relapse was 45.1+/-13.7 months. In contrast, 21 of 22 patients (95 percent) with antibodies against both MOG and MBP had a relapse within a mean of 7.5+/-4.4 months, and 35 of 42 patients (83 percent) with only anti-MOG antibodies had a relapse within 14.6+/-9.6 months (P<0.001 for both comparisons with antibody-seronegative patients). The adjusted hazard ratio for the development of clinically definite multiple sclerosis was 76.5 (95 percent confidence interval, 20.6 to 284.6) among the patients who were seropositive for both antibodies and 31.6 (95 percent confidence interval, 9.5 to 104.5) among the patients who were seropositive only for anti-MOG antibodies, as compared with the seronegative patients. CONCLUSIONS: Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. This finding may be important for the counseling and care of patients with a first demyelinating event suggestive of multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Lehmann, P. V., Forsthuber, T., Miller, A., & Sercarz, E. E. (1992) · Nature · doi:10.1038/358155a0 · Cited by 1,186
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Epitope spreading in immune-mediated diseases: implications for immunotherapy
Vanderlugt, C. L., & Miller, S. D. (2002) · Nature Reviews Immunology · doi:10.1038/nri724 · Cited by 950
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Self-citationMiller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Keegan, M., König, F., McClelland, R., Brück, W., Morales, Y., Bitsch, A., Panitch, H., Lassmann, H., Weinshenker, B., Rodriguez, M., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67102-4 · Cited by 433
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O'Connor, K. C., McLaughlin, K. A., De Jager, P. L., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar-Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 416
Chen, J. J., Flanagan, E. P., Jitprapaikulsan, J., López-Chiriboga, A. (. S., Fryer, J. P., Leavitt, J. A., Weinshenker, B. G., McKeon, A., Tillema, J.-M., Lennon, V. A., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.020 · Cited by 408
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390
Self-citationHöftberger, R., Guo, Y., Flanagan, E. P., Lopez-Chiriboga, A. S., Endmayr, V., Hochmeister, S., Joldic, D., Pittock, S. J., Tillema, J. M., Gorman, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02132-y · Cited by 369
Karussis, D. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.022 · Cited by 366
Corcione, A., Casazza, S., Ferretti, E., Giunti, D., Zappia, E., Pistorio, A., Gambini, C., Mancardi, G. L., Uccelli, A., & Pistoia, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402455101 · Cited by 349
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Tintoré, M., Rovira, A., Río, J., Tur, C., Pelayo, R., Nos, C., Téllez, N., Perkal, H., Comabella, M., Sastre-Garriga, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000280576.73609.c6 · Cited by 345
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Sechi, E., Cacciaguerra, L., Chen, J. J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.885218 · Cited by 325
Brilot, F., Dale, R. C., Selter, R. C., Grummel, V., Reddy Kalluri, S., Aslam, M., Busch, V., Zhou, D., Cepok, S., & Hemmer, B. (2009) · Annals of Neurology · doi:10.1002/ana.21916 · Cited by 322
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
Pröbstel, A. K., Dornmair, K., Bittner, R., Sperl, P., Jenne, D., Magalhaes, S., Villalobos, A., Breithaupt, C., Weissert, R., Jacob, U., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c0b1 · Cited by 306
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Comabella, M., Fernández, M., Martin, R., Rivera-Vallvé, S., Borrás, E., Chiva, C., Julià, E., Rovira, A., Cantó, E., Alvarez-Cermeño, J. C., et al. (2010) · Brain · doi:10.1093/brain/awq035 · Cited by 300
The neuro-ophthalmology of multiple sclerosis
Frohman, E. M., Frohman, T. C., Zee, D. S., McColl, R., & Galetta, S. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)00992-0 · Cited by 285
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Ramanathan, S., Dale, R. C., & Brilot, F. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.12.004 · Cited by 281
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Antigen microarray profiling of autoantibodies in rheumatoid arthritis
Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., Fries, J. F., Sønderstrup, G., Monach, P., Drijfhout, J. W., van Venrooij, W. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21269 · Cited by 261
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)
Glatigny, S., & Bettelli, E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028977 · Cited by 247
Zhang, Z., Zoltewicz, J. S., Mondello, S., Newsom, K. J., Yang, Z., Yang, B., Kobeissy, F., Guingab, J., Glushakova, O., Robicsek, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092698 · Cited by 200
“Fro example, measurement of autoantibodies by western blot-based methods might have limited clinical applications [63–65].”
MethodThe node of Ranvier in CNS pathology
Arancibia-Carcamo, I. L., & Attwell, D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1305-z · Cited by 177
Mechanistic biomarkers for clinical decision making in rheumatic diseases
Robinson, W. H., Lindstrom, T. M., Cheung, R. K., & Sokolove, J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.14 · Cited by 109
CNS-resident classical DCs play a critical role in CNS autoimmune disease
Giles, D. A., Duncker, P. C., Wilkinson, N. M., Washnock-Schmid, J. M., & Segal, B. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123708 · Cited by 99
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD
Yan, Y., Li, Y., Fu, Y., Yang, L., Su, L., Shi, K., Li, M., Liu, Q., Borazanci, A., Liu, Y., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-015-4997-y · Cited by 63
Sakuma, H. (2004) · Brain · doi:10.1093/brain/awh260 · Cited by 59
Jagessar, S. A., Smith, P. A., Blezer, E., Delarasse, C., Pham-Dinh, D., Laman, J. D., Bauer, J., Amor, S., & 't Hart, B. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a6851 · Cited by 50
Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain
Dang, P. T., Bui, Q., D’Souza, C. S., & Orian, J. M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_378 · Cited by 35
“2013), as well as a correlation between anti-MOG antibody status in serum after a first demyelinating event [or clinically isolated syndrome (CIS)] and risk for conversion to definite MS (Berger et al. 2003; Kuhle et al. 2007).”
BackgroundPotential role of regulatory B cells in immunological diseases
Valizadeh, A., Sanaei, R., Rezaei, N., Azizi, G., Fekrvand, S., Aghamohammadi, A., & Yazdani, R. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.08.004 · Cited by 16
Metadata
- Authors
- Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-10
- Volume
- 349
- Issue
- 2
- Pages
- 139-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2074074558
- Cited by
- 616
- References
- 34
- FWCI
- 33.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.